Any current/future capex/capital investment/strategic investment?

The company plans to open 15 new centres annually, a mix of hubs and spokes, with leases signed for upcoming hubs like Gulbarga and Mahabubnagar, indicating ongoing capital expenditure. Expansion efforts include creating a dense network in both home markets (Andhra Pradesh and Telangana) and new regions like Kolkata, aiming for significant growth over 3-5 years. No concrete inorganic acquisitions are currently planned, but the company remains open to evaluating meaningful opportunities aligned with value, brand recall, and quality, provided valuations are reasonable. New hub centres are being

Future growth expectations in sales/revenue/volumes?

The company targets consistent double-digit growth, aiming for around 14% to 15% revenue growth in the near future. High or mid-double-digit growth is expected driven by ramp-up of new hub and spoke centres. Opening 15 new centres annually (a mix of hubs and spokes) is planned, supporting expansion. New markets like Kolkata are viewed as longer-term growth opportunities, with intentions to build dense networks over 3-4 years. Non-COVID business volume grew 20% year-on-year, reflecting robust demand in radiology and pathology. Wellness segment is expanding, now contributing 12.4% of revenue, up

Future growth expectations in earnings/operating earnings/profits/EPS?

Vijaya Diagnostic Centre expects continued double-digit revenue growth, targeting around 14-15% year-on-year growth in the near future. New hubs, including Kolkata, Gulbarga, and Mahabubnagar, will drive high double-digit growth initially before normalizing. Expansion includes opening about 15 centers annually, comprising both hubs and spokes, supporting volume and revenue growth. EBITDA margins remain healthy around 40%, with operational breakeven targeted within 12 months for new centers like Kolkata and Tirupati. Profit after Tax (PAT) growth was approximately 16-17% adjusting for d

Vijaya Diagnost.Q1 FY24Healthcare Services

Vijaya Diagnost. Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,428P/E: 83.2Market Cap: ₹15.6K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company targets consistent double-digit growth, aiming for around 14% to 15% revenue growth in the near future.
High or mid-double-digit growth is expected driven by ramp-up of new hub and spoke centres.
Opening 15 new centres annually (a mix of hubs and spokes) is planned, supporting expansion.
New markets like Kolkata are viewed as longer-term growth opportunities, with intentions to build dense networks over 3-4 years.
Non-COVID business volume grew 20% year-on-year, reflecting robust demand in radiology and pathology.
Wellness segment is expanding, now contributing 12.4% of revenue, up from 9.6%.
Digital initiatives enhancing customer experience (single billing, multiple services) are expected to support volume growth.
The integrated model and customer preference for personal touch support sustained footfall and volume increases.

Margin guidance

Category 3

Vijaya Diagnostic Centre expects continued double-digit revenue growth, targeting around 14-15% year-on-year growth in the near future.
New hubs, including Kolkata, Gulbarga, and Mahabubnagar, will drive high double-digit growth initially before normalizing.
Expansion includes opening about 15 centers annually, comprising both hubs and spokes, supporting volume and revenue growth.
EBITDA margins remain healthy around 40%, with operational breakeven targeted within 12 months for new centers like Kolkata and Tirupati.
Profit after Tax (PAT) growth was approximately 16-17% adjusting for depreciation policies; excluding special hub impacts, PAT growth could be around 30-31%.
Volume growth of tests is strong at 20% year-on-year, supporting revenue and profit expansion, with a growing wellness segment contributing more to revenue.
The company is optimistic about sustained earnings performance supported by a strong B2C integrated model and investments in technology and quality.

See what Vijaya Diagnost. management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript does not mention any current or planned fundraising through debt or equity. Key points related to this are: - The company is focused on sustainable expansion and intelligent market research. - They are open to inorganic growth opportunities if they make sense financially and strategically but currently have no concrete plans. - No specific comments about raising capital through debt or equity were provided during the call. - Emphasis is on operational growth via new hubs and spokes, and organic ramp-up of existing centers. - Cash and cash equivalents stood at INR 280 crores at the end of the quarter, indicating liquidity. In summary, there is no explicit indication of any immediate or future fundraising through debt or equity in the disclosed information.

Order book

The provided transcript from Vijaya Diagnostic Centre Limited's Q1 FY24 earnings call does not explicitly mention details about current or expected orderbook or pending orders. Key highlights include: - Strategic expansion focus with opening of new hubs such as Kolkata, Gulbarga, and Mahabubnagar. - No specific mention of orderbook or pending orders in the Q&A or management commentary. - The company is always evaluating inorganic opportunities but currently has no concrete acquisition plans. - Growth is driven mainly by new centre ramp-up and improved performance in existing centres. - Management focuses on sustainable expansion guided by research and quality asset acquisition. If further details on orderbook or pending orders are needed, it's recommended to reach out directly to the company or investor relations for specific updates.

See what Vijaya Diagnost. management said on order book — free account, 30 seconds.

Capex plans

Yes

The company plans to open 15 new centres annually, a mix of hubs and spokes, with leases signed for upcoming hubs like Gulbarga and Mahabubnagar, indicating ongoing capital expenditure.
Expansion efforts include creating a dense network in both home markets (Andhra Pradesh and Telangana) and new regions like Kolkata, aiming for significant growth over 3-5 years.
No concrete inorganic acquisitions are currently planned, but the company remains open to evaluating meaningful opportunities aligned with value, brand recall, and quality, provided valuations are reasonable.
New hub centres are being launched, including a futuristic hub in Kolkata with advanced equipment like 3 Tesla MRI and 128 slice cardiac CT, requiring significant capital investment.
Overall focus on sustainable expansion guided by intelligent market research and investment in high-end technology to build brand leadership in new and existing markets.

Track Vijaya Diagnost. — get its next earnings analysis in your feed

How does Vijaya Diagnost. rank vs peers in Healthcare Services?

Pro feature

ThisVijaya Diagnost.

Rev 3Mar 3

See where Vijaya Diagnost. sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Vijaya Diagnost. rank in Healthcare Services?

Compare Vijaya Diagnost. against every Healthcare Services company (Q1 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Suven Life Sciences Ltd (Q1 FY22)
The provided pages of the Suven Life Sciences investor presentation do not contain any specific revenue, sales, or volume figures for any quarter. Key concall…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Vijaya Diagnost. Q1 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Vijaya Diagnost. rank in Healthcare Services?

Continue your research

What Vijaya Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season